Iris Grossman

List of Publications by Year
in descending order

34 papers	1,116 citations	361413 20 h-index	477307 29 g-index
37 all docs	37 docs citations	37 times ranked	1731 citing authors

#	Article	IF	Citations
1	Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6145-E6152.	7.1	111
2	The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. Neurobiology of Disease, 2017, 97, 46-59.	4.4	105
3	Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. European Journal of Human Genetics, 2009, 17, 946-957.	2.8	89
4	Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenetics and Genomics, 2007, 17, 657-666.	1.5	74
5	Pridopidine activates neuroprotective pathways impaired in Huntington Disease. Human Molecular Genetics, 2016, 25, 3975-3987.	2.9	65
6	TOMM40 and APOE: Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial. Alzheimer's and Dementia, 2013, 9, 132-136.	0.8	59
7	Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. Genetics in Medicine, 2007, 9, 826-835.	2.4	56
8	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinsonâ€™s disease: a pharmacogenetic study. Brain, 2016, 139, 2050-2062.	7.6	53
9	Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genetics in Medicine, 2008, 10, 720-729.	2.4	48
10	Characterization of the Poly-T Variant in the TOMM40 Gene in Diverse Populations. PLoS ONE, 2012, 7, e30994.	2.5	47
11	Routine pharmacogenetic testing in clinical practice: dream or reality?. Pharmacogenomics, 2007, 8, 1449-1459.	1.3	43
12	Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI Insight, 2017, 2, .	5.0	39
13	Alzheimerâ€™s disease: diagnostics, prognostics and the road to prevention. EPMA Journal, 2010, 1, 293-303.	6.1	36
14	Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes. Pharmacogenomics, 2008, 9, 847-868.	1.3	33
15	Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research. Progress in Neurobiology, 2017, 152, 114-130.	5.7	29
16	Characterizing patient compliance over six months in remote digital trials of Parkinsonâ€™s and Huntington disease. BMC Medical Informatics and Decision Making, 2018, 18, 138.	3.0	26
17	Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. Molecular Neurodegeneration, 2018, 13, 25.	10.8	26
18	Discovery and Targeting of the Signaling Controls of PNPLA3 to Effectively Reduce Transcription, Expression, and Function in Pre-Clinical NAFLD/NASH Settings. Cells, 2020, 9, 2247.	4.1	26

#	Article	IF	Citations
19	ADME pharmacogenetics: current practices and future outlook. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 449-462.	3.3	25
20	A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis. Genome Medicine, 2017, 9, 50.	8.2	25
21	Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition. Journal of Neuroimmunology, 2016, 290, 84-95.	2.3	21
22	Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). Evidence Report/technology Assessment, 2007, , 1-77.	1.3	21
23	Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids. Scientific Reports, 2015, 5, 10191.	3.3	14
24	Trick or treat: The effect of placebo on the power of pharmacogenetic association studies. Human Genomics, 2005, 2, 28.	2.9	10
25	Pipeline Pharmacogenetics: A Novel Approach to Integrating Pharmacogenetics into Drug Development. Current Pharmaceutical Design, 2009, 15, 3754-3763.	1.9	9
26	Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics. EPMA Journal, 2010, 1, 317-327.	6.1	8
27	Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model. Annals of the New York Academy of Sciences, 2017, 1407, 75-89.	3.8	7
28	Healthy aging and preclinical dementia: The United States-Israel Longitudinal Database Project. , 2010, 6, 475-481.		5
29	Pharmacogenetics and Pharmacogenomics. , 2010, , 175-190.		3
30	Biobanking in Israel 2016â€“17; expressed perceptions versus real life enrollment. BMC Medical Ethics, 2017, 18, 63.	2.4	1
31	Roadmap to Drug Development Enabled by Pharmacogenetics. Advances in Predictive, Preventive and Personalised Medicine, 2015, , 43-67.	0.6	1
32	Pharmacogenetics and Pharmacogenomics. , 2009, , 321-334.		0
33	Cytochrome P450 testing in the treatment of depression. , 2009, , 597-619.		0
34	Clinical Trials of AD Delay of Onset: Enrichment by a Prognostic Genetic Biomarker. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 141-160.	0.6	0